# D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study

Study · id `cardio:ct-nct04784039` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04784039](<https://clinicaltrials.gov/study/NCT04784039>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04784039

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1368 participants.

## Technical summary

Registry record NCT04784039. Randomized; no masking; primary purpose prevention. Start 2025-01-01 (anticipated); primary completion 2026-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1368 participants (planned count; ClinicalTrials.gov record NCT04784039, source copy `cardio:ctgov-nct04784039-2023-02-01`, retrieved 2026-10-26)
- Planned start: 2025-01-01 (anticipated) (ClinicalTrials.gov record NCT04784039, source copy `cardio:ctgov-nct04784039-2023-02-01`, retrieved 2026-10-26)
- Primary completion: 2026-01-31 (anticipated) (ClinicalTrials.gov record NCT04784039, source copy `cardio:ctgov-nct04784039-2023-02-01`, retrieved 2026-10-26)
- Completion: 2026-01-31 (anticipated) (ClinicalTrials.gov record NCT04784039, source copy `cardio:ctgov-nct04784039-2023-02-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04784039-2023-02-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study
- Acronym: CARDDI-BEL
- Condition: Atrial Fibrillation
- Intervention (Diagnostic test): Transesophageal echocardiography
- Intervention (Diagnostic test): D-Dimer analysis
- Lead sponsor: AZ Sint-Jan AV
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: AZ Sint-Jan AV (`cardio:org-az-sint-jan-av`)

## Provenance

Content hash: 080fba8b5184c8144d0000e23a2d856bc77917ca9d46c0de6f7b740f94f36b79
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
